Pfizer Gets Rapid FDA Approval For New Lung Cancer Drug

The U.S. Food and Drug Administration rushed approval for a new lung cancer drug developed by Pfizer called Crizotinib, The Wall Street Journal reports.

Shares of Pfizer rose 3.2% to $18.79 in premarket trading and have continued to rise since the the market opened.

Critzonib is specifically made for lung cancer patients with a rare genetic abnormality that strikes those least at risk of developing the disease– young non-smokers. To be taken twice daily, it shrinks tumors forming inside the lungs by stopping a gene called ALK from spurring their growth.

Each year 200,000 people are diagnosed with lung cancer. About 3-5% of them have the form that could be treated with Crizotinib. The drug will cost $9,600 a month, and with co-pay assistance for eligable, privately-insured patients, it should cost patients no more than $100.

The company, along with Bristol-Meyers Squibb, is also testing a new stroke prevention medication, called apixaban. In recent tests, apixaban reduced the risk of stroke in patients with a heartbeat irregularity called atrial fibrillation by 21%.

Here’s what the stock looks like right now:

chart

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at research.businessinsider.com.au.